Description
ADO-Trastuzumab Emtansine, marketed under the brand name KADCYLA, It is an prescription medication that has been approved ado-trastuzumab emtansine (KADCYLA) for the treatment of HER2-positive early breast cancer on May 3, 2019.
What is Kadcyla (Ado-Trastuzumab emtansine) ?
KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for: The treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.
How to order approved “Kadcyla (Ado-Trastuzumab emtansine) for Injection” Medicine?
KADCYLA (ADO-Trastuzumab Emtansine) Injection is a prescription medicine, it can be accessed through the Named Patient Program (NPP) for treatment in the following city of India – Bengaluru, Delhi, Chennai, Hyderabad, Mumbai, Pune, Kolkata, Ahmedabad, Gurgaon. To inquire about the cost price of purchasing KADCYLA and arranging delivery to your location, please get in touch with Mr. Rakesh at +91 9910645395 or send an enquiry to info@cancermedicinesnetwork. We assure you of the quality of the product and guarantee delivery in accordance with your specific requirements.
